EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
独家报道：温和肽类（GLP-1）减肥药物可能成为万亿美元市场，Tema etf 的首席执行官预测。
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.
根据Tema etf的创始人兼首席执行官Maurits Pot在接受Benzinga的独家采访时的乐观预测，GLP-1类药物肥胖治疗市场预计将飙升至1万亿美元或更高。
"Our view is that in the long term, this is not a two-horse race between Eli Lilly Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO)," Maurits stated, challenging the prevailing notion of a duopoly in the weight-loss market.
"我们认为，从长远来看，这并不是伊利莎白・莉莉公司（NYSE:LLY）和诺和诺德有限公司（NYSE:NVO）之间的两马戏表演，" Maurits称，挑战了减肥市场垄断的主流观念。
Pot predicts that rising demand for weight loss treatments and expanded applications for GLP-1 drugs will drive this trillion-dollar market opportunity...
Pot预计，减肥治疗需求和GLP-1药物的扩...
登录免费看全文
登录/注册